Reviva Pharmaceuticals (NASDAQ:RVPH) & Cassava Sciences (NASDAQ:SAVA) Head-To-Head Survey

Cassava Sciences (NASDAQ:SAVA) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cassava Sciences and Reviva Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1	1	0	0	1.50
Reviva Pharmaceuticals	1	0	7	1	2.89

Cassava Sciences presently has a consensus target price of $2.00, suggesting a potential downside of 10.75%. Reviva Pharmaceuticals has a consensus target price of $3.86, suggesting a potential upside of 1,258.15%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Cassava Sciences.

Earnings & Valuation

This table compares Cassava Sciences and Reviva Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$24.34 million	($2.19)	-1.02
Reviva Pharmaceuticals	N/A	N/A	-$29.92 million	($0.46)	-0.62

Cassava Sciences is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cassava Sciences has a beta of -1.08, suggesting that its stock price is 208% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500.

Profitability

This table compares Cassava Sciences and Reviva Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-63.39%	-49.81%
Reviva Pharmaceuticals	N/A	-20,501.80%	-187.50%

Institutional & Insider Ownership

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 2.4% of Cassava Sciences shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Reviva Pharmaceuticals beats Cassava Sciences on 9 of the 12 factors compared between the two stocks.

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.